Chen-Kiang, Selina

Publications

Sort by

Co-Author Network

selected publications

Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma. Blood advances. 2023 Academic Article GET IT
PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma. Blood advances. 2023 Academic Article GET IT
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas. Cancer cell. 2023 Academic Article GET IT
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood. 2023 Academic Article GET IT
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation. Nature communications. 2023 Academic Article GET IT
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 9
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. Experimental hematology & oncology. 2022 Academic Article GET IT
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER⁺ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 48
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematology/oncology clinics of North America. 2020 Information Resource GET IT
Immunomodulation by anticancer cell cycle inhibitors. Nature reviews. Immunology. 2020 Information Resource GET IT
Times cited: 99
Targeting CDK4/6 in mantle cell lymphoma. Annals of lymphoma. 2020 Academic Article GET IT
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 11
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 64
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer research. 2018 Academic Article GET IT
Times cited: 60
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 7
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 43
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 143
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2015 Academic Article GET IT
Times cited: 44
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 49
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer research. 2015 Academic Article GET IT
Times cited: 44
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Academic Article GET IT
Times cited: 125
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 240
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 7
Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Critical reviews in oncology/hematology. 2013 Information Resource GET IT
Times cited: 15
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell cycle (Georgetown, Tex.). 2013 Academic Article GET IT
Times cited: 68
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Academic Article GET IT
Times cited: 98
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 20
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Academic Article GET IT
Times cited: 32
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 258
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer cell. 2012 Academic Article GET IT
Times cited: 150
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Academic Article GET IT
Times cited: 74
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 Academic Article GET IT
Times cited: 236
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 89
Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood. 2010 Academic Article GET IT
Times cited: 23
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2010 Academic Article GET IT
Times cited: 119
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010 Academic Article GET IT
Times cited: 46
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer immunity. 2010 Academic Article GET IT
Times cited: 41
Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 66
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 30
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 254
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 50
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 95
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer research. 2008 Academic Article GET IT
Times cited: 92
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 63
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 161
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British journal of haematology. 2007 Academic Article GET IT
Times cited: 79
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer research. 2006 Academic Article GET IT
Times cited: 180
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer research. 2005 Academic Article GET IT
Times cited: 90
Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 38
Biology of plasma cells. Best practice & research. Clinical haematology. 2005 Information Resource GET IT
Times cited: 14
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proceedings of the National Academy of Sciences of the United States of America. 2004 Academic Article GET IT
Times cited: 52
AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004 Academic Article GET IT
Times cited: 365
Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood. 2003 Academic Article GET IT
Times cited: 74
Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunological reviews. 2003 Information Resource GET IT
Times cited: 46
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. Journal of immunology (Baltimore, Md. : 1950). 2003 Academic Article GET IT
Times cited: 113
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. Journal of immunology (Baltimore, Md. : 1950). 2002 Academic Article GET IT
Times cited: 58
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity. 2002 Academic Article GET IT
Times cited: 79
Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. The Journal of experimental medicine. 2000 Academic Article GET IT
Times cited: 380
Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription. European journal of immunology. 2000 Academic Article GET IT
Times cited: 16
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes & development. 1998 Academic Article GET IT
Times cited: 352
Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. Immunity. 1997 Academic Article GET IT
Times cited: 50
Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity. 1997 Academic Article GET IT
Times cited: 132
Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proceedings of the National Academy of Sciences of the United States of America. 1996 Academic Article GET IT
Times cited: 203
Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (New York, N.Y.). 1995 Academic Article GET IT
Times cited: 510
Activation of the TSG-6 gene by NF-IL6 requires two adjacent NF-IL6 binding sites. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 16
Simultaneous activation of Ig and Oct-2 synthesis and reduction of surface MHC class II expression by IL-6. Journal of immunology (Baltimore, Md. : 1950). 1994 Academic Article GET IT
Times cited: 12
NF-IL6 and AP-1 cooperatively modulate the activation of the TSG-6 gene by tumor necrosis factor alpha and interleukin-1. Molecular and cellular biology. 1994 Academic Article GET IT
Times cited: 78
Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region. Molecular and cellular biology. 1994 Academic Article GET IT
Times cited: 196
Convergent regulation of NF-IL6 and Oct-1 synthesis by interleukin-6 and retinoic acid signaling in embryonal carcinoma cells. Molecular and cellular biology. 1993 Academic Article GET IT
Times cited: 41
NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. Journal of virology. 1992 Academic Article GET IT
Times cited: 83
Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proceedings of the National Academy of Sciences of the United States of America. 1991 Academic Article GET IT
Times cited: 46
Adenovirus E1A and E1B genes are regulated posttranscriptionally in human lymphoid cells. Journal of virology. 1990 Academic Article GET IT
Times cited: 11
Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. Proceedings of the National Academy of Sciences of the United States of America. 1989 Academic Article GET IT
Times cited: 60
Preparation of precursors to mRNA from mammalian cell nuclei. Methods in enzymology. 1989 Academic Article GET IT
Times cited: 10
Pulse labeling of heterogeneous nuclear RNA in isolated nuclei. Methods in enzymology. 1989 Academic Article GET IT
Times cited: 16
Productive infection of cultured human lymphoid cells by adenovirus. Journal of virology. 1987 Academic Article GET IT
Times cited: 49
Cell-type-specific synthesis of murine immunoglobulin mu RNA from an adenovirus vector. Molecular and cellular biology. 1986 Academic Article GET IT
Times cited: 18
Pausing and premature termination of human RNA polymerase II during transcription of adenovirus in vivo and in vitro. Proceedings of the National Academy of Sciences of the United States of America. 1984 Academic Article GET IT
Times cited: 70
Premature termination by human RNA polymerase II occurs temporally in the adenovirus major late transcriptional unit. Molecular and cellular biology. 1984 Academic Article GET IT
Times cited: 40
Transcription and accurate polyadenylation in vitro of RNA from the major late adenovirus 2 transcription unit. Cell. 1982 Academic Article GET IT
Times cited: 29
Processing of adenovirus nuclear RNA to mRNA. Advances in virus research. 1981 Academic Article GET IT
Times cited: 15
The addition of 5' cap structures occurs early in hnRNA synthesis and prematurely terminated molecules are capped. Cell. 1980 Academic Article GET IT
Times cited: 86
N-6-methyl-adenosine in adenovirus type 2 nuclear RNA is conserved in the formation of messenger RNA. Journal of molecular biology. 1979 Academic Article GET IT
Times cited: 72
Characterization of proteins and peptides by high-performance liquid chromatography and fluorescence monitoring of their tryptic digests. Analytical biochemistry. 1979 Academic Article GET IT
Times cited: 65
Gel electrophoresis of fluorescent labeled cyanogen bromide cleavage products at the submicrogram level. Analytical biochemistry. 1979 Academic Article GET IT
Times cited: 13
Expression of collagen biosynthetic activities in lymphocytic cells. Proceedings of the National Academy of Sciences of the United States of America. 1978 Academic Article GET IT
Times cited: 23
Homology between a prolyl hydroxylase subunit and a tissue protein that crossreacts immunologically with the enzyme. Proceedings of the National Academy of Sciences of the United States of America. 1977 Academic Article GET IT
Times cited: 27

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Service Agreement from Peter MacCallum - PI: Dr. Tam awarded by Peter MacCallum Cancer Centre Principal Investigator 2020 - 2025
Mechanism-Based Targeting of Mantle Cell Lymphoma awarded by National Cancer Institute Principal Investigator 2018 - 2025
missing activity Principal Investigator 2018 - 2023

missing activity Key Personnel 2021 - 2024

more ...

less ...

Background

education and training

Ph.D., Columbia University 1977
B.S., National Taiwan University (Taiwan) 1967
M.S., Cornell University 1967

Contact

full name

Selina Chen-Kiang

primary email

sckiang@med.cornell.edu

VIVO Weill Cornell Medical College

Selina Chen-Kiang Professor of Pathology and Laboratory Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email